Coronary angiographic assessment of streptokinase efficacy in young patients with ST-elevation myocardial infarction
Keywords:
Acute myocardial infarction; Mortality; Streptokinase; ST-elevation myocardial infarction; Thrombolytic therapy; Young adultAbstract
Background: Thrombolytic therapy has emerged as one of the most effective interventions for acute myocardial infarction, a condition that is the leading cause of mortality worldwide.
Aims and Objectives: This study aimed to evaluate the efficacy and clinical outcomes of Streptokinase (SK) in young patients with ST-elevation myocardial infarction (STEMI) based on coronary angiography performed 12–24 h post-thrombolysis.
Materials and Methods: This observational, cross-sectional study included 50 patients diagnosed with STEMI of age between 18 and 40 years and treated with SK between September 2022 and August 2023 in India. The efficacy of SK was assessed through coronary angiography performed 12–24 h post-thrombolysis and ST-segment resolution on electrocardiogram. Clinical outcomes, including adverse events and mortality, were recorded.
Results: The majority of patients (66%) were 31–40 years old, with males constituting 88% of the population. Single vessel disease was predominant (84%) among the study population. Anterior wall myocardial infarction emerged as the predominant type of infarction, accounting for 56% of patients in the present study. Successful thrombolysis was achieved in 67.85% of patients treated within 3 h of symptom onset. Adverse events occurred in 52% of patients, with left ventricular failure being the most frequent complication (36%), followed by arrhythmia (26%). The study observed a relatively low mortality rate of 8% among young patients with STEMI.
Conclusion: Coronary angiography findings demonstrate that SK is effective in treating young patients with STEMI, particularly when administered within 3 h of symptom onset. Despite frequent adverse events, mortality rates remained low.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Asian Journal of Medical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- The journal holds copyright and publishes the work under a Creative Commons CC-BY-NC license that permits use, distribution and reprduction in any medium, provided the original work is properly cited and is not used for commercial purposes. The journal should be recognised as the original publisher of this work.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
